AR059176A1 - Compuesto de indol, composicion farmaceutica que lo comprende, metodo para prepararlo y su uso para preparar dicha composicion y para la manufactura de un medicamento para el tratamiento o prevencion de leiomiomas y endometriosis. - Google Patents

Compuesto de indol, composicion farmaceutica que lo comprende, metodo para prepararlo y su uso para preparar dicha composicion y para la manufactura de un medicamento para el tratamiento o prevencion de leiomiomas y endometriosis.

Info

Publication number
AR059176A1
AR059176A1 ARP070100303A ARP070100303A AR059176A1 AR 059176 A1 AR059176 A1 AR 059176A1 AR P070100303 A ARP070100303 A AR P070100303A AR P070100303 A ARP070100303 A AR P070100303A AR 059176 A1 AR059176 A1 AR 059176A1
Authority
AR
Argentina
Prior art keywords
alkyl
haloalkyl
alkenyl
cycloalkyl
heteroaryl
Prior art date
Application number
ARP070100303A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR059176A1 publication Critical patent/AR059176A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Steroid Compounds (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)

Abstract

Un compuesto de indol de la formula (1): en donde n es 1 o 2; R1 se selecciona de: alquilo C1-6, alquenilo C2-6, alquinilo C2-6, hidroxialquilo C1-6, haloalquilo C1-6, alquilarilo C1-6, alquilheteroarilo C1-6, cicloalquilo C3-8, alquilcicloalquilo C1-6, alquilheterociclilo C1-6, arilo, heteroarilo, alquilo C1-6-O-R9, alquilo C0-6 C(S)R9, alquilo C0-6COR9, -C(O)NR9R10, -SOnR11, en donde cada uno de los cicloalquilo, heterociclilo, arilo, y heteroarilo se enlistan ya sea singularmente o en combinacion con una porcion alquilo son opcionalmente substituidos, con un grupo seleccionado de: halo, -CN, -OH, oxo, alquilo C1-3, haloalquilo C1-3, alquilciano C1-3, alquenilo C2-5, alquilo C0-C3 NO-2, -O-alquilo C1-3, hidroxialquilo C1-3, alquilo C0-3NR12R13, alquilo C0-3C(O)R12, alquilo C0-3C(O)OR12, -C(O)NR12R1 3, -C(S)NR12R13, -CH2OR12, -SR12, -S(O)nR12, -S(O)nNR12R13, -N(R9)C(O)NR12R13, -N(R12)C(O)OR13, -N(R12)S(O)nR13, -N(R12)S(O)nNR12R13, -C=N-OR12, y -cicloCN4R9; con la condicion de que arilo y heteroarilo no son di o tri substituidos con substituyentes alcoxi; R2 se selecciona de H, halo, -CN, alquilo C1-6, haloalquilo C1-8, cicloalquilo C3-8, alquenilo C2-6, alquinilo C2-6, en donde el cicloalquilo es opcionalmente substituido con un grupo seleccionado de: halo, -CN, -OH, oxo, alquilo C1-3, haloalquilo C1-3, cianoalquilo C1-3, alquenilo C2-5, alquilo C0-3-NO-2, -O-alquilo C1-3, y hidroxialquilo C1-3; R3 se selecciona de un arilo opcionalmente substituido o un heteroarilo opcionalmente substituido; en donde el arilo substituido y el heteroarilo substituido se substituye con un grupo seleccionado de: halo, -CN, -OH, oxo, alquilo C1-3, haloalquilo C1-3, alquilciano C1-3, alquenilo C2-5, alquilo C0-3 NO-2, -O-alquilo C1-3, hidroxialquilo C1-3, alquilo C0-3NR12R13, alquilo C0-3C(O)R12, alquilo C0-C3C(O)OR12, -C(O)NR12R13, -C(S)NR12R13, -CH2OR12, -SR12, -S(O)nR12, -S(O)nNR12R13, -N(R9)C(O)NR12R13, -N(R12)C(O)OR13, -N(R12)S(O)nR13, - N(R12)S(O)nNR12R13, y -C=N-OR12; R4, R5, y R7 son cada uno independientemente seleccionados de: H, halo, -OH, -CN, alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, -O-alquilo C1-6, -O-haloalquilo C1-6; R6 se selecciona de: alquilo C1- 6, haloalquilo C1-6, alquilheterociclilo C1-6, alquilheteroarilo C0-6, cicloalquilo C3-8, alquilcicloalquilo C1-6, alquenilo C2-6, heterociclilo, alquilo C0-6NR9R10, y -N(H)C(O)R9, en donde cada uno de los cicloalquilo, heterociclilo, y heteroarilo se enlistan ya sea singularmente o en combinacion con una porcion alquilo son opcionalmente substituidos con uno o más grupos seleccionados de halo, -CN, -OH, oxo, alquilo C1-3, haloalquilo C1-3, alquilciano C1-3, alquenilo C2-5, alquilo C0-3NO2, -O- alquilo C1-3, y hidroxialquilo C1-3; R8 se selecciona de: H, alquilo C1-4, haloalquilo C1-4; R9 y R10 son individualmente seleccionados de: H, alquilo C1-6, haloalquilo C1-6, alquilheterociclilo C0-6, alquilcicloalquilo C1-6 alquilarilo C1-6, alquilheteroarilo C0-6, hidroxialquilo C1-6, alquenilo C2-6, cicloalquilo C3-8, o R9 y R10 junto con el átomo al cual se enlazan forman un anillo cíclico de 4 hasta 7 miembros que contiene 0-2 heteroátomos y en donde cada uno de los anillo cíclicos, heterociclilo, cicloalquilo, arilo, y heteroarilo se enlistan ya sea singularmente o con una porcion alquilo son opcionalmente substituidos; R11 se selecciona de: alquilo C1-6, -NR9R10, alquilcicloalquilo C0-6, arilo, heteroarilo en donde cada uno de los cicloalquilo, arilo, y heteroarilo se enlistan ya sea singularmente o en combinacion con una porcion alquilo son opcionalmente substituidos con un grupo seleccionado de: halo, -CN, -OH, oxo, alquilo C1-3, haloalquilo C1-3, cianoalquilo C1-3, alquenilo C2-5, alquilo C0-3NO2-, -O- alquilo C1-3, e hidroxialquilo C1-3; R12 y R13 son individualmente seleccionados de: H, alquilo C1-6, haloalquilo C1-6, alquilcicloalquilo C1-6, alquilarilo C1-6, alquilheteroarilo C0-6, hidroxialquilo C1-6, alquenilo C2-6, y cicloalquilo C3-8; o una sal farmacéuticamente aceptable del mismo. Método para su preparacion, composiciones farmacéuticas que lo comprenden, y su uso para prepararlas. El compuesto es util para modular la actividad del receptor de progesterona, en especial sirve para tratar y/o prevenir leiomiomas o las secuelas patologicas debido a endometriosis en un mamífero.
ARP070100303A 2006-01-24 2007-01-24 Compuesto de indol, composicion farmaceutica que lo comprende, metodo para prepararlo y su uso para preparar dicha composicion y para la manufactura de un medicamento para el tratamiento o prevencion de leiomiomas y endometriosis. AR059176A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US76163706P 2006-01-24 2006-01-24

Publications (1)

Publication Number Publication Date
AR059176A1 true AR059176A1 (es) 2008-03-12

Family

ID=38180657

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100303A AR059176A1 (es) 2006-01-24 2007-01-24 Compuesto de indol, composicion farmaceutica que lo comprende, metodo para prepararlo y su uso para preparar dicha composicion y para la manufactura de un medicamento para el tratamiento o prevencion de leiomiomas y endometriosis.

Country Status (31)

Country Link
US (1) US7932284B2 (es)
EP (1) EP1979314B1 (es)
JP (1) JP4912414B2 (es)
KR (1) KR101126895B1 (es)
CN (1) CN101374808B (es)
AR (1) AR059176A1 (es)
AU (1) AU2007208109B2 (es)
BR (1) BRPI0706411A2 (es)
CA (1) CA2637933C (es)
CR (1) CR10236A (es)
DK (1) DK1979314T3 (es)
DO (1) DOP2007000018A (es)
EA (1) EA014470B1 (es)
EC (1) ECSP088641A (es)
ES (1) ES2399112T3 (es)
HK (1) HK1124328A1 (es)
HR (1) HRP20130058T1 (es)
IL (1) IL192021A (es)
MA (1) MA30207B1 (es)
MY (1) MY146494A (es)
NO (1) NO20083553L (es)
NZ (1) NZ568910A (es)
PE (1) PE20071245A1 (es)
PT (1) PT1979314E (es)
SI (1) SI1979314T1 (es)
SV (1) SV2008002986A (es)
TN (1) TNSN08311A1 (es)
TW (1) TWI368613B (es)
UA (1) UA94600C2 (es)
WO (1) WO2007087488A2 (es)
ZA (1) ZA200805757B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009094224A1 (en) 2008-01-25 2009-07-30 Millennium Pharmaceuticals, Inc. Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
CN102395585A (zh) 2009-01-30 2012-03-28 米伦纽姆医药公司 杂芳基化合物和其作为pi3k抑制剂的用途
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
JP5687704B2 (ja) * 2009-10-07 2015-03-18 カロ バイオ アクチェブラーグ 新規エストロゲン受容体リガンド
CA2807971A1 (en) 2010-08-11 2012-02-16 Millenium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9062038B2 (en) 2010-08-11 2015-06-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
EP2603216A4 (en) 2010-08-11 2013-12-18 Millennium Pharm Inc HETEROARYLE AND USES THEREOF
UY33671A (es) 2010-10-13 2012-04-30 Millenium Pharmaceuticals Inc Heteroarilos y sus usos
GB201113538D0 (en) 2011-08-04 2011-09-21 Karobio Ab Novel estrogen receptor ligands
AR091731A1 (es) 2012-07-19 2015-02-25 Merck Sharp & Dohme Antagonistas del receptor de mineralocorticoides
MX2016015005A (es) 2014-05-15 2017-09-28 Iteos Therapeutics Derivados de pirrolidina-2,5-diona, composiciones farmaceuticas y metodos para usar como inhibidores ido1.
MA41140A (fr) 2014-12-12 2017-10-17 Cancer Research Tech Ltd Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
CN104529866A (zh) * 2014-12-12 2015-04-22 广东东阳光药业有限公司 吲哚类衍生物及其在药物上的应用
MA41179A (fr) 2014-12-19 2017-10-24 Cancer Research Tech Ltd Composés inhibiteurs de parg
KR102013512B1 (ko) 2015-03-17 2019-08-22 화이자 인코포레이티드 신규 3-인돌 치환 유도체, 제약 조성물 및 사용 방법
EP3334733A1 (en) 2015-08-10 2018-06-20 Pfizer Inc 3-indol substituted derivatives, pharmaceutical compositions and methods for use
CN105906530A (zh) * 2016-04-27 2016-08-31 昆药集团股份有限公司 一种绿色环保的卤代芳基甲氰的制备方法
EP3454945B1 (en) * 2016-05-12 2022-01-19 The Regents Of The University Of Michigan Ash1l inhibitors and methods of treatment therewith
WO2019094773A1 (en) 2017-11-10 2019-05-16 The Regents Of The University Of Michigan Ash1l inhibitors and methods of treatment therewith
CN114903996B (zh) * 2022-06-22 2023-10-20 武汉大学中南医院 Hedgehog通路的特异性抑制剂在制备用于治疗宫腔粘连的药物中的应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9317764D0 (en) 1993-08-26 1993-10-13 Pfizer Ltd Therapeutic compound
US5756507A (en) * 1995-12-14 1998-05-26 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
CA2271767A1 (en) * 1996-11-19 1998-05-28 Nathan B. Mantlo Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents
DE19749453A1 (de) 1997-11-10 1999-05-12 Hoechst Marion Roussel De Gmbh Sulfonamid-substituierte anellierte 5-Ring-Verbindungen, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
PL343007A1 (en) 1998-02-25 2001-07-30 Genetics Inst Inhibitors of phospholipase enzymes
US6417214B1 (en) * 1999-05-04 2002-07-09 Wyeth 3,3-substituted indoline derivatives
EP1432706A2 (en) 2001-09-26 2004-06-30 Bayer Pharmaceuticals Corporation 3-pyridyl or 4-isoquinolinyl thiazoles as c17,20 lyase inhibitors
ES2187300B1 (es) 2001-11-14 2004-06-16 Laboratorios Del Dr. Esteve, S.A. Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
EP1314733A1 (en) 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
US6933316B2 (en) * 2001-12-13 2005-08-23 National Health Research Institutes Indole compounds
US7247333B2 (en) * 2003-03-19 2007-07-24 Pepsico Inc. Stabilized milk product containing fruit and fruit juice
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
KR20050036982A (ko) 2002-08-29 2005-04-20 베링거 인겔하임 파마슈티칼즈, 인코포레이티드 염증, 알러지 및 증식성 질환의 치료에 글루코코르티코이드모사체로 사용하기 위한 3-(설폰아미도에틸)-인돌 유도체
ES2313002T3 (es) 2003-05-09 2009-03-01 Laboratorios Del Dr. Esteve, S.A. Uso de derivados de sulfonamida para la fabricacion de un medicamento para la profilaxis y/o tratamiento de la ingestion de alimentos.
ES2222832B1 (es) 2003-07-30 2006-02-16 Laboratorios Del Dr. Esteve, S.A. Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos.
WO2005014543A1 (ja) 2003-08-06 2005-02-17 Japan Tobacco Inc. 縮合環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用
WO2005056522A2 (en) 2003-12-04 2005-06-23 National Health Research Institutes Indole compounds
CA2557745A1 (en) 2004-03-03 2005-10-06 Eli Lilly And Company Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators
JP5070042B2 (ja) 2004-05-03 2012-11-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 選択的アンドローゲン受容体モジュレーター（ｓａｒｍｓ）としての新規インドール化合物
AU2005302706B2 (en) 2004-10-27 2011-12-15 Janssen Pharmaceutica N.V. Indole derivatives useful as progesterone receptor modulators

Also Published As

Publication number Publication date
WO2007087488A3 (en) 2007-09-13
US7932284B2 (en) 2011-04-26
TNSN08311A1 (en) 2009-12-29
KR101126895B1 (ko) 2012-03-20
AU2007208109B2 (en) 2012-08-23
ECSP088641A (es) 2008-08-29
EP1979314B1 (en) 2013-01-09
HK1124328A1 (en) 2009-07-10
DK1979314T3 (da) 2013-02-04
UA94600C2 (en) 2011-05-25
CA2637933C (en) 2013-03-12
DOP2007000018A (es) 2007-08-31
BRPI0706411A2 (pt) 2011-03-29
JP2009526762A (ja) 2009-07-23
KR20080088609A (ko) 2008-10-02
IL192021A (en) 2013-02-28
NO20083553L (no) 2008-10-20
CN101374808B (zh) 2011-05-25
IL192021A0 (en) 2008-12-29
PT1979314E (pt) 2013-03-05
SV2008002986A (es) 2010-01-18
SI1979314T1 (sl) 2013-02-28
TW200738631A (en) 2007-10-16
WO2007087488A9 (en) 2008-08-28
EA200870196A1 (ru) 2009-02-27
JP4912414B2 (ja) 2012-04-11
ZA200805757B (en) 2009-11-25
EP1979314A2 (en) 2008-10-15
TWI368613B (en) 2012-07-21
EA014470B1 (ru) 2010-12-30
MY146494A (en) 2012-08-15
PE20071245A1 (es) 2008-01-30
AU2007208109A1 (en) 2007-08-02
CA2637933A1 (en) 2007-08-02
CR10236A (es) 2008-11-28
NZ568910A (en) 2011-04-29
CN101374808A (zh) 2009-02-25
WO2007087488A2 (en) 2007-08-02
US20090069400A1 (en) 2009-03-12
MA30207B1 (fr) 2009-02-02
HRP20130058T1 (hr) 2013-02-28
ES2399112T3 (es) 2013-03-25

Similar Documents

Publication Publication Date Title
AR059176A1 (es) Compuesto de indol, composicion farmaceutica que lo comprende, metodo para prepararlo y su uso para preparar dicha composicion y para la manufactura de un medicamento para el tratamiento o prevencion de leiomiomas y endometriosis.
AR082029A1 (es) Derivados de heterociclos nitrogenados, composiciones y metodos para modular la via de señalizacion de wnt
AR071617A1 (es) Bencenosulfonamidas de oxazol y tiazol, composiciones farmaceuticas que las contienen, proceso de preparacion y uso de las mismas como agentes anticancerigenos.
AR056317A1 (es) Compuestos de oxindol y composicion farmaceutica
AR082111A1 (es) Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas
AR074411A1 (es) Compuestos heterociclicos fungicidas
AR081797A1 (es) Derivados de pirrolidinona heteroaromaticas fusionadas, composiciones farmaceuticas que las contienen y uso de las mismas para tratar afecciones del sistema inmune y la inflamacion
AR063912A1 (es) Derivados de 1,2,4 oxadiazol. composiciones farmaceuticas.
AR086319A1 (es) Compuestos heterociclicos fusionados como moduladores de canal ionico
AR061564A1 (es) Derivados de isoindoles, composiciones farmaceuticas y usos
AR043015A1 (es) Compuestos moduladores de amida derivada de quinolina del receptor vanilloide vr1, composiciones farmaceuticas y veterinarias que los contienen y su uso en el tratamiento de enfermedades afectadas por la modulacion de dichos receptores
AR045260A1 (es) Compuestos que contienen imidazo-oxima sustituidos
AR084849A1 (es) Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos
AR049300A1 (es) Compuestos triciclicos antagonistas de mglur1 como agentes terapeuticos
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR083199A1 (es) Compuestos de n-heteroarilo con unidad de puente ciclico
AR083367A1 (es) Compuestos de tipo quinazolinona como antagonistas de crth
AR043434A1 (es) Derivados de piperizacina acilados como agonistas del receptor de melanocortina-4. composiciones farmaceuticas y usos
AR044402A1 (es) Compuestos heterociclicos y su uso como inmunodepresores. composiciones farmaceuticas que los contienen.
AR053713A1 (es) Compuestos heterociclicos y sus usos como agentes terapeuticos
AR044874A1 (es) Derivados de 4- cianopirazol-3 - carboxamida, su preparacion y su aplicacion en terapeutica
AR069509A1 (es) Pirido (3,2-e) pirazinas, su procedimiento de preparacion y uso como inhibidores de fosfodiesterasa 10
AR077365A1 (es) Derivados de imidazol para el tratamiento de enfermedades mediadas por la inhibicion de la formacion de abeta
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
PE20090620A1 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen

Legal Events

Date Code Title Description
FA Abandonment or withdrawal